Mayo Clinic Ventures
VC Fund
Rochester, United States
Mayo Clinic Ventures is a VC fund in Rochester focused on Health Care and Biotechnology. Mayo Clinic Ventures is dedicated to quickly bringing answers to the people who need them most: the patients living with diseases and conditions that threaten to limit or even end their lives. Our team works closely with Mayo physicians and scientists to mine inventions, ideas and discoveries that will truly transform health care. Their dedicatedefforts bring significant financial support to Mayo's patient care, education and research efforts.
- Total investments:
- 49
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $2M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Mayo Clinic Ventures invests in
Stages Mayo Clinic Ventures invests in
Countries Mayo Clinic Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.4M–$5.9M
- Series A
- $5M–$26M
- Series B
- $6.5M–$60M
Investment Focus
Industry
- Health Care 28 (57%)
- Biotechnology 17 (35%)
- Therapeutics 10 (20%)
- Medical 9 (18%)
- Medical Device 8 (16%)
Stage
- Seed 12 (24%)
- Series A 10 (20%)
- Series B 10 (20%)
- Series C 7 (14%)
- Venture - Series Unknown 3 (6%)
Country
- United States 27 (55%)
- Israel 3 (6%)
- Ireland 2 (4%)
- China 1 (2%)
- Switzerland 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrew Badley
Professor & Chair, Dept of Molecular Medicine
|
Professor & Chair, Dept of Molecular Medicine | Total investments: 0 | Find email | |
Greg Worrell
Professor Neurology & Division Chair of Clinical Neurophysiology
|
Professor Neurology & Division Chair of Clinical Neurophysiology | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| UltraSight aims to revolutionize ultrasound through the power of machine learning to enable more accurate and timely clinical decisions. The UltraSight automated guidance system helps bring the benefits of cardiac imaging to healthcare professionals in new care settings, allowing patients access to ultrasound anywhere. UltraSight won the TCT 2020Innovation Competition which took place during the Transcatheter Cardiovascular Therapeutics world conference. For mor information please visit us at www.ultrasight.com | $24M / Series B / Sep 23, 2026 | ||
| Online integrative pain management. | $11M / Series A / Dec 08, 2025 | ||
| Anumana develops AI algorithms that analyze ECG data to support early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing tools that assist healthcare professionals in identifying potential heart issues. Anumana's platform extends beyond diagnostics, aiming to improvepatient outcomes throughout the entire continuum of cardiovascular care, including perioperative and acute settings. By utilizing machine learning techniques, Anumana aims to refine screening processes, making it easier for clinicians to detect heart diseases and intervene promptly. This approach contributes to more efficient healthcare delivery and better management of cardiovascular health. | Series C / Apr 24, 2025 | ||
| Myosin Therapeutics is a privately-held biopharmaceutical company developing novel medications for CNS-based disorders. The company specializes in molecular machines that turn energy into mechanical work inside cells, enabling doctors to treat various disease states, including cancer, and focuses on developing innovative drugs that target cellularmotor proteins. | $3M / Seed / Feb 26, 2025 | ||
| JOGO Health is a virtual care company that uses clinically proven digital interventions to treat pain, neuromuscular, movement and pelvic floor disorders. The company's AI-driven mobile app and wearable sensors provide treatments for conditions like stroke, chronic pain, and pelvic health by tapping into the brain's neuroplasticity. | $5.5M / Venture - Series Unknown / Jun 18, 2024 | ||
| AccuLine is a digital healthcare company, which was founded with the vision to saves the lives of millions of people worldwide. AccuLine is developing CORA—a smart, accurate, and easy to use exam for the early detection of coronary artery disease. The clinically validated CORA evaluates a patient's risk of having coronary artery diseasethrough advanced analysis and detection of two newly discovered biomarkers in the heart’s electrical activity. CORA’s early detection will assist in the prevention of sudden cardiac deaths, while lowering costs of cardiovascular related illness. | $3.5M / Seed / May 01, 2024 | ||
| Qlaris Bio focuses on developing novel and innovative therapies for serious and debilitating ophthalmic diseases. Qlaris Bio is a spinout company of Qrativ, a biotechnology incubator formed as a joint venture between Mayo Clinic and inference, a pharmaceutical-focused artificial intelligence company. Its lead program is QLS-101, a novel compoundinvented at Mayo Clinic and the University of Minnesota. QLS-101, with its unique and first-in-class mechanism of action, may potentially serve as an efficacious treatment for high unmet need conditions related to disturbances in intraocular pressure, including a sight-threatening and progressive Pediatric Rare Disease for which effective therapies remain elusive and limited.Qlaris Bio was founded in 2019 and is headquartered in Cambridge, Massachusetts. | $24M / Series B / Apr 22, 2024 | ||
| Online integrative pain management. | $5.2M / Series A / Feb 07, 2024 | ||
| Quai MD is a developer of AI-based platform intended to help doctors to diagnose patients accurately in real-time. The company's platform collects pathways, personalizes them using its in-house AI engine, allowing the doctor to customize the pathway to the particular patient while giving them complete freedom to take any path they seesuitable.Quai MD was established in 2020 by Shlomi Uziel, Golan Yona, Chen Shapira MD, and Lia Weiner in Tel Aviv-yafo, Israel. | $4.8M / Pre-Seed / Jul 23, 2023 | ||
| Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developedat the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring. | $5.9M / Seed / Dec 17, 2022 | ||
| See all 49 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Mayo Clinic Ventures invest in?
Mayo Clinic Ventures invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Seed and Series A stage. Most of the 49 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Mayo Clinic Ventures's check size?
Mayo Clinic Ventures typically joins rounds of $1.4M–$5.9M at Seed, $5M–$26M at Series A and $6.5M–$60M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Mayo Clinic Ventures participates in.
How do I contact Mayo Clinic Ventures?
Public channels for Mayo Clinic Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Mayo Clinic Ventures?
The team at Mayo Clinic Ventures includes Andrew Badley (Professor & Chair, Dept of Molecular Medicine) and Greg Worrell (Professor Neurology & Division Chair of Clinical Neurophysiology). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
